NCT05706155Toboroz
Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management
Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management: A Randomized Clinical Trial
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jan. 29.
Rövid összefoglaló (regiszter, angolul)
The goal of this clinical trial is to examine the effect plant-based diet, with a partial replacement of animal protein by plant protein, in blood sugar levels and other health risks of people with type 2 diabetes and excessive weight. The plant-based diet will be compared to a standard healthy diet according to guidelines for people with diabetes. Participants will follow a plant-based or a standard healthy diet for 24 weeks and will maintain their habitual levels of physical activity.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 146 (tervezett)
- Első benyújtás
- 2022. dec. 23.
- Kezdés
- 2022. nov. 1.
- Elsődleges befejezés
- 2027. dec. 30.
- Fő szponzor
- Hospital de Clinicas de Porto Alegre
- Betegségek
- 2-es típusú cukorbetegség, Elhízás
- NCT-szám
- NCT05706155
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 146
- 2022. nov. 1. és az elsődleges befejezés (2027. dec. 30.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Prior stroke that has caused sequelae;
- Chronic treatment with oral or parenteral corticosteroids (>7 days consecutive treatment) within 4 weeks prior to screening;
- Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening;
- Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening;
- Having undergone bariatric surgery;
Más betegség
- Type 1 diabetes mellitus;
- Chronic kidney disease with estimated glomerular filtration < 30 mL/min per 1.73m²;
- Liver failure, chronic viral hepatitis;
- Grade III or IV heart failure
- Active or progressive neurodegenerative disease;
- History of active substance abuse (including alcohol) within the last year;
- Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years;
- Severe psychiatric illness;
- Predisposition or diagnosis of eating disorders;
- Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma;
- Carriers of the human immunodeficiency virus (HIV);
- Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities;
Laborértékek
- Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss;
- Fasting triglycerides ≥ 600 mg/dL;
Egyéb
- Retinopathy with vision deficit that limits the activities proposed in the interventions;
- Thyroid Stimulating Hormone (TSH) outside the normal range;
- Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding;
- Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months;
- Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study;
- Night workers who work after 10pm;
- Being on a vegetarian, vegan or flexitarian diet at the time of recruitment;
- Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.
Kiket keres a vizsgálat
- Adults (≥18 and ≤65 years old)
- Diagnosis of Type 2 Diabetes;
- Glycated hemoglobin from 7% to 11%;
- Overweight or obesity (BMI ≥25 kg/m² and <40 kg/m²);
- Use of any hypoglycemic and insulin;
- Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening;
- Not having undergone dietary intervention in the last 6 months;
- Have the ability to understand and be able to adhere to intervention proposals;
- Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol;
Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Hospital de Clinicas de Porto Alegre | Porto Alegre | Brazília | Toboroz |
Kapcsolódó publikációk
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.